Results 81 to 90 of about 429 (97)

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Lancet, The, 2019
Stefan Kasper, Hans-Georg Kopp, Georg Martin Haag   +2 more
exaly  

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Lancet, The, 2019
Edward F Mckone, Damian G Downey, Eva Van Braeckel   +2 more
exaly  

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Lancet, The, 2013
Dieter Hoelzer
exaly  

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

Lancet, The, 2016
Shaodong Hong, Xuan Wu, Rensheng Wang
exaly  

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Lancet, The, 2010
Johann Sebastian de Bono, Stephane Oudard, Steinbjørn Hansen   +2 more
exaly  

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

Lancet, The, 2019
Avraham Eisbruch, Paul M Harari, Erich M Sturgis   +2 more
exaly  

Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial

Lancet, The, 2016
Nicolino Ruperto, Angela Pistorio, Sheila k Oliveira   +2 more
exaly  

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Lancet, The, 2014
Edward B Garon, Oscar Arrieta, Keunchil Park   +2 more
exaly  

PHONE COUNSELING PLUS MEDICATION HELP EVEN HEAVY SMOKERS QUIT

Ca-A Cancer Journal for Clinicians, 2006
exaly  

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial

Lancet, The, 2015
Tarik Asselah, K Rajender Reddy, Marina Berenguer   +2 more
exaly